More than three decades ago, a discovery rooted in Nigeria's natural landscape began a journey that would evolve into a focused pharmaceutical effort addressing one of the most pressing unmet needs in modern medicine. Immune Modulation, Inc., a California-based biotech company founded in 1995, is built around that journey, translating a plant-derived compound into a drug candidate now being prepared for regulatory pathways in Parkinson's disease.
Dr. Emmanuel A. Ojo-Amaize, the company's founder and CEO, explains that the origins of the work trace back to a compound identified by Professor Joseph Okogun, a natural products chemist in Nigeria. "We were not starting with a finished idea," he says. "We were starting with a question about what this compound could actually do, and that question shaped everything that followed." According to him, early external evaluations had not identified significant applications for the compound, which led the team to examine it from a different perspective.
That shift in thinking became foundational. Rather than focusing on enhancing immune responses, the team explored how the compound interacted with inflammatory pathways. Dr. Ojo-Amaize notes that this approach led to the realization that the compound functioned as an anti-inflammatory agent, opening up a range of potential applications. "We decided to look at the opposite side of the immune response, and that is where we found something meaningful," he explains.
The process was neither immediate nor straightforward. Dr. Olusola A. Oyemade, Managing Director, explains that the team evaluated more than 70 plant extracts before identifying the compound that would later be developed into hypoestoxide. "Before we arrived at this result, there was a long period of testing and elimination," he says. "The eventual discovery was the outcome of sustained scientific exploration rather than a single breakthrough moment."
Over time, the research expanded into multiple areas, but the most significant turning point came between 2013 and 2015, when the compound's neurological potential was explored in collaboration with academic research institutions. Dr. Howard B. Cottam, co-founder and Vice President, explains that in preclinical studies, hypoestoxide was evaluated in models of Parkinson's disease, where it demonstrated measurable biological effects. "In those studies, we observed that hypoestoxide reduced neuroinflammation and decreased the accumulation of alpha-synuclein in the brain," he says. "Those findings gave us a clearer understanding of how the compound interacts with pathways associated with Parkinson's disease."
Parkinson's disease represents a substantial global health challenge. According to research, it affects approximately 1% of the population over the age of 60, and demographic trends indicate continued growth in that population segment. At the same time, Dr. Cottam notes that currently available treatments are largely focused on symptom management rather than altering disease progression.
Within that context, Immune Modulation has positioned hypoestoxide as a potential disease-modifying candidate. Dr. Cottam notes that the compound's mechanism has been associated with reducing the accumulation of specific proteins linked to neurodegeneration. "The goal is to address the process itself, not only the symptoms that appear later," he explains. He further acknowledges that further validation through clinical studies remains necessary.
The company's development strategy reflects a structured progression through scientific and regulatory milestones. "Preclinical studies are nearing completion, and we are now preparing for submission to the U.S. FDA, including the final toxicology and pharmacokinetic studies required to move forward," Dr. Oyemade says. "This stage represents a shift from research into formal clinical development, and it calls for a different level of infrastructure, resources, and operational support."
To support this transition, the company is seeking $20 million in funding, which it intends to use to advance the drug through early-stage clinical trials. According to Dr. Ojo-Amaize, the objective is to reach Phase 2A studies, where proof of concept in patients can be evaluated. "This is the point where the work moves from potential to measurable clinical outcomes," he explains. "The company has already invested significant resources over the past decades to reach its current position."
Beyond the scientific and financial considerations, the company's narrative is also shaped by a broader shift in how treatments are perceived. "There is growing interest in naturally sourced therapeutics as people become more mindful of what they put into their bodies," Dr. Ojo-Amaize says. "When developed under modern pharmaceutical standards, these compounds offer a strong path forward." He emphasizes that the compound itself has not been structurally modified, but instead purified to meet regulatory requirements. "We are working with what nature provided, and refining it to a level that meets clinical expectations," he says.
For Immune Modulation, the combination of long-term research, a defined clinical pathway, and a clearly identified unmet need forms the basis of its current positioning. Dr. Oyemade reflects on the duration of the effort as a defining characteristic. "This has been a sustained commitment over many years," he says. "What matters now is translating that work into something that can reach patients."
As the company advances toward regulatory engagement, its story reflects both persistence and timing. A discovery that began in a rainforest setting has evolved into a focused clinical ambition, shaped by decades of research and a renewed interest in therapies that address disease at its source.
